Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New registry to monitor fabry drug safety in pregnant women and newborns

NCT ID NCT06941025

First seen Apr 05, 2026 · Last updated May 21, 2026 · Updated 7 times

Summary

This study is a worldwide registry that will follow about 10 women with Fabry disease who received the drug pegunigalsidase alfa around the time of pregnancy or while breastfeeding. Researchers will track pregnancy outcomes and infant health for up to one year after birth. The goal is to better understand the safety of this treatment for both mothers and babies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREGNANCY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • No physical study sites - Decentralized, web-based registry

    RECRUITING

    Washington D.C., District of Columbia, 20001, United States

  • No physical study sites - Decentralized, web-based registry

    RECRUITING

    Berlin, Germany

  • No physical study sites - Decentralized, web-based registry

    RECRUITING

    Rome, Italy

  • No physical study sites - Decentralized, web-based registry

    RECRUITING

    Madrid, Spain

  • No physical study sites - Decentralized, web-based registry

    NOT_YET_RECRUITING

    London, United Kingdom

Conditions

Explore the condition pages connected to this study.